Get all premium features to the best stock analysis tool

Finranks

Finranks

Company

  • About us

Contact us

  • [email protected]

Follow us

  • Instagram
  • Telegram
  • LinkedIn

All rights reserved.

Privacy PolicyTerms of Conditions
  • Home
  • Markets
  • Screener
  • News
  • About
  1. Home
  2. VRTX
V

Vertex Pharmaceuticals Incorporated (VRTX)

NMS – Real Time Price. Currency in USD

433.07

-20.67 (-4.56%)

At close: Mar 27, 2026, 4:00 PM EDT

434.00

+0.93 (0.21%)

After-hours: Mar 27, 2026, 7:49 PM EDT

  • Summary
  • News
  • Chart
  • Financial
  • Dividends
  • Forecast
  • Ownership
  • Profile

Stock details

Previous close
433.07$
Day's range
431.01 - 452$
52-week range
362.5 - 510.77$
Volume
1 915 620
Average volume
1 457 141
Beta
0.39
EPS (TTM)
15.47
PE ratio (TTM)
28.24
Market cap
110 014 590 666
Shares outstanding
254 034 199
Dividend yield
N/A
Next earnings date
2026-05-06
Sector
Healthcare
Industry
Biotechnology

About the company

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del m... read more
CEO
Reshma Kewalramani
Country
United States
IPO Date
1991-07-24
Employees
6400
Fiscal Year End
January - December
Website
https://www.vrtx.com

Revenue Breakdown

Pharmaceuticals / 100.00%

News

No Data

There are no news for this stock.

Chart: VRTX

Loading Chart...

Overall Score

6.4 / 1064%
Financial Strength
9.6
Profitability
9.4
Effectiveness
7.5
Growth
7.4
Forecast
6.3
Valuation
4.3

Financial Strength

NAMERATIOINDUSTRY5Y TRENDSCORE
Current ratio2.906.0510
Quick ratio2.465.6310
Debt to Equity0.110.309.0
Debt to Assets0.081.049.0
Interest coverage394.06-16.9110
Weighted average score9.6

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)
Values in USD (B=Billions, M=Millions, K=Thousands)
METRIC2022202320242025TTM
Total Revenue8.75B9.84B10.98B12.07B12.07B
Gross Profit7.67B8.58B9.45B10.27B10.42B
Operating Income4.18B4.28B4.36B4.76B4.76B
Net Income3.32B3.62B-536M3.95B3.95B
EBITDA4.33B4.46B4.57B4.97B4.97B

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAMERATIOINDUSTRY5Y TRENDSCORE
Gross margin %85.56-11.73
10
Operating margin %40.30-24.60
10
Net margin %36.91-172.20
10
EBITDA margin %41.94-201.27
10
Cash flow margin %15.43-156.39
7.0
Weighted average score9.4

Net Margin

Effectiveness

NAMERATIOINDUSTRY5Y TRENDSCORE
ROA10.98-57.97
9.0
ROE15.49-63.56
8.0
ROIC14.11-42.57
7.0
ROCE5.82-71.10
6.0
Weighted average score7.5

Estimated EPS vs Actual EPS

Forecast

NAMEREVENUE GROWTHEPS GROWTHSCORE
Current quarter10.710.047.0
Next quarter9.274.85.0
Current year8.8955.0
Next year10.2215.188.0
Weighted average score6.3

Analyst Rating

Growth

NAMEREVENUENET INCOMEEPSFCFSCORE
Q/Q3.599.994.79-69.43.8
Y/Y11.7630.4626.38-29.147.0
3y average11.34244.091395.36121.839.3
5y average14.31152.1845.381.789.5
Weighted average score7.4

Revenue Growth Rate vs. Industry

Valuation

NAMERATIOINDUSTRY5Q TRENDSCORE
P/E29.63-5.25
4.0
PEG (5yr expected)2.220.27
4.0
P/S9.7664.66
6.4
P/B6.182.96
2.8
Weighted average score4.3

DCF Model

DCF Model Period5 years
Discount rate8.50%
Perpetual growth rate3%
Revenue 5 year CAGR21.5%
FCF 5 year CAGR5
Fair value327.91$
Stock price433.07$

Dividend

NAMECURRENTINDUSTRYSCORE
Dividend yield0.00N/A1.0
Payout ratio0.00N/A1.0
5-year dividend growth rateN/AN/A1.0
Years of dividend increaseN/AN/A1.0
Weighted average score1.0

Fair Value

Fair Value

$327.91

UndervaluedStock priceOvervalued

$433.07

Economic Moat

NAMESCALESCORE
Market shareMedium7.0
Intangible assetsWide8.0
Switching costsMedium5.0
Network effectNone1.0
Economies of scaleMedium6.0
Weighted average score5.4
Dividend
1
Economic Moat
5.4

Octagon View

Strength & Weakness

Company's cash reserves $5.1B significantly exceed its total debt $2.0B, ensuring strong financial flexibility

Total current assets $11.2B exceed Total current liabilities $3.9B, highlighting excellent liquidity

Debt-to-equity ratio (0.1) is well below the industry average (0.3), showcasing prudent financial management

Interest coverage ratio (394x) indicates the company easily manages its debt payments

The company generates positive free cash flow $348.6M, supporting its financial health